YAP1 and cancer: Mutations in YAP/TAZ itself are rare and limited to certain cancer types; thus, recent investigations correlate YAP/TAZ oncogenic activation in solid tumors to “wounds that never heal”, as YAP is activated following extensive damage (due to radiation and/or chemotherapy), and in cooperation with oncogenic mutations driving proliferative pathways (such as RAS/MAPK, etc.), cooperate to drive a chronic regenerative response [40].